XML 24 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statement of Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Statement [Abstract]      
Sales $ 48,704 $ 41,518 $ 39,121
Costs, Expenses and Other      
Cost of sales 13,626 13,618 12,016
Selling, general and administrative 9,634 8,955 9,455
Research and development 12,245 13,397 9,724
Restructuring costs 661 575 626
Other (income) expense, net (1,341) (890) 129
Total costs, expenses and other 34,825 35,655 31,950
Income from Continuing Operations Before Taxes 13,879 5,863 7,171
Taxes on Income from Continuing Operations 1,521 1,340 1,565
Net Income from Continuing Operations 12,358 4,523 5,606
Less: Net Income (Loss) Attributable to Noncontrolling Interests 13 4 (84)
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 12,345 4,519 5,690
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 704 2,548 4,153
Net Income Attributable to Merck & Co., Inc. $ 13,049 $ 7,067 $ 9,843
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders      
Income from Continuing Operations (in dollars per share) $ 4.88 $ 1.79 $ 2.22
Income from Discontinued Operations (in dollars per share) 0.28 1.01 1.62
Net Income (in dollars per share) 5.16 2.79 3.84
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders      
Income from Continuing Operations (in dollars per share) 4.86 1.78 2.21
Income from Discontinued Operations (in dollars per share) 0.28 1.00 1.61
Net Income (in dollars per share) $ 5.14 $ 2.78 $ 3.81